Pub Date : 2024-11-01Epub Date: 2024-12-02DOI: 10.1016/j.jaim.2024.100993
P Parvathy, G S Lekha, S Aparna, A Kanagarajan
Diabetic Nephropathy is one of the major microvascular complications of Diabetes Mellitus, which can be detected in the earlier stage by investigating urinary microalbumin excretion levels and estimating ACR and GFR. Early treatment can delay or prevent the progression of diabetic Nephropathy. Monoherbal Siddha formulation Sirupeelai Kudineer indicated for the complications of Diabetes Mellitus is selected for this Case study. The efficiency of the drug was assessed by measuring the change in renal function throughout the treatment period and the KD QOL assessment. Four patients presented with symptoms of Diabetic Nephropathy were treated with the monoherbal Siddha formulation Sirupeelai Kudineer. This series of four cases showed improvement in CKD QOL and some biochemical parameters. Blood urea was reduced in the four cases during medication. Serum creatinine levels mildly increased in three cases somewhere during the treatment period but decreased in all four cases after treatment. The estimated GFR also improved in three cases after treatment but mildly reduced in one patient. Symptomatic improvement was also observed in all the patients. Marked reduction in blood urea and serum creatinine levels after treatment shows the Nephroprotective action of the drug. The clinical and laboratory parameters observed among these four patients suggest that this drug may be used along with other hypoglycemic drugs to treat Diabetic Nephropathy.
{"title":"Treatment of early-stage diabetic nephropathy with Siddha drug Sirupeelai Kudineer: A case series.","authors":"P Parvathy, G S Lekha, S Aparna, A Kanagarajan","doi":"10.1016/j.jaim.2024.100993","DOIUrl":"10.1016/j.jaim.2024.100993","url":null,"abstract":"<p><p>Diabetic Nephropathy is one of the major microvascular complications of Diabetes Mellitus, which can be detected in the earlier stage by investigating urinary microalbumin excretion levels and estimating ACR and GFR. Early treatment can delay or prevent the progression of diabetic Nephropathy. Monoherbal Siddha formulation Sirupeelai Kudineer indicated for the complications of Diabetes Mellitus is selected for this Case study. The efficiency of the drug was assessed by measuring the change in renal function throughout the treatment period and the KD QOL assessment. Four patients presented with symptoms of Diabetic Nephropathy were treated with the monoherbal Siddha formulation Sirupeelai Kudineer. This series of four cases showed improvement in CKD QOL and some biochemical parameters. Blood urea was reduced in the four cases during medication. Serum creatinine levels mildly increased in three cases somewhere during the treatment period but decreased in all four cases after treatment. The estimated GFR also improved in three cases after treatment but mildly reduced in one patient. Symptomatic improvement was also observed in all the patients. Marked reduction in blood urea and serum creatinine levels after treatment shows the Nephroprotective action of the drug. The clinical and laboratory parameters observed among these four patients suggest that this drug may be used along with other hypoglycemic drugs to treat Diabetic Nephropathy.</p>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"100993"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-12-09DOI: 10.1016/j.jaim.2024.101047
Sri Lestariningsih, Didik Gunawan Tamtomo, Sri Sulistyowati, Dono Indarto, Soetrisno Soetrisno, Hanik Badriyah Hidayati, Wahyudi Widada
Background: Primary dysmenorrhea (PD) is characterized by discomfort with no organic etiology (no pelvic disease), recurring pain, or lower abdominal cramps that start between the first 8-72 h of menstruation. Cupping therapy uses a tool to form a vacuum at certain points on the skin.
Objectives: We investigated the mechanism of pain relief caused by cupping therapy in primary dysmenorrhea that is played by cupping therapy in PD. This study aimed to investigate the effects of the cupping method on pain symptoms, changes in PGF2α, PGE, and β-endorphin levels, and uterine morphology in PD.
Methods: A total of 35 female rats were divided into five groups (n = 7 rats per group): control, PD, dysmenorrhea treated with dry cupping (DC), dysmenorrhea treated with wet cupping (WC), and dysmenorrhea treated with ibuprofen (IB) as a standard drug. Pain was assessed by measuring the degree of writhing pain. Serum PGF2α, PGE, and β-endorphin levels were evaluated using ELISA. Hematoxylin-eosin staining was used to examine uterine morphology, such as thickness, vacuolization, and inflammation.
Results: WC had a pain normalization effect comparable to that of ibuprofen. Ibuprofen is superior to both types of cupping in reducing the PGF2α/PGE ratio and the PGF2α to β-endorphins ratio. WC and DC have capabilities comparable to those of ibuprofen in improving uterine vacuolization and inflammation.
Conclusions: These results indicate that WC is more effective than DC in suppressing dysmenorrhea symptoms, modulating the hormone level ratio, and repairing uterine pathology. The potential benefits of cupping provide an opportunity for further studies in human subjects.
{"title":"Effects of wet cupping in a rat model of primary dysmenorrhea.","authors":"Sri Lestariningsih, Didik Gunawan Tamtomo, Sri Sulistyowati, Dono Indarto, Soetrisno Soetrisno, Hanik Badriyah Hidayati, Wahyudi Widada","doi":"10.1016/j.jaim.2024.101047","DOIUrl":"10.1016/j.jaim.2024.101047","url":null,"abstract":"<p><strong>Background: </strong>Primary dysmenorrhea (PD) is characterized by discomfort with no organic etiology (no pelvic disease), recurring pain, or lower abdominal cramps that start between the first 8-72 h of menstruation. Cupping therapy uses a tool to form a vacuum at certain points on the skin.</p><p><strong>Objectives: </strong>We investigated the mechanism of pain relief caused by cupping therapy in primary dysmenorrhea that is played by cupping therapy in PD. This study aimed to investigate the effects of the cupping method on pain symptoms, changes in PGF2α, PGE, and β-endorphin levels, and uterine morphology in PD.</p><p><strong>Methods: </strong>A total of 35 female rats were divided into five groups (n = 7 rats per group): control, PD, dysmenorrhea treated with dry cupping (DC), dysmenorrhea treated with wet cupping (WC), and dysmenorrhea treated with ibuprofen (IB) as a standard drug. Pain was assessed by measuring the degree of writhing pain. Serum PGF2α, PGE, and β-endorphin levels were evaluated using ELISA. Hematoxylin-eosin staining was used to examine uterine morphology, such as thickness, vacuolization, and inflammation.</p><p><strong>Results: </strong>WC had a pain normalization effect comparable to that of ibuprofen. Ibuprofen is superior to both types of cupping in reducing the PGF2α/PGE ratio and the PGF2α to β-endorphins ratio. WC and DC have capabilities comparable to those of ibuprofen in improving uterine vacuolization and inflammation.</p><p><strong>Conclusions: </strong>These results indicate that WC is more effective than DC in suppressing dysmenorrhea symptoms, modulating the hormone level ratio, and repairing uterine pathology. The potential benefits of cupping provide an opportunity for further studies in human subjects.</p>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"101047"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Ayurvedic formulations need to be explored and tested with biomedical techniques. Polyherbal medicated ghee (Ghrita) are recommended for the management of epilepsy (Apasmara) and prepared using specialized process (Snehapaka), as per classical textbooks of Ayurveda. So, the present study deals with the systematic examination of the effect of different marketed formulations for treating Apasmara on convulsive impairment in Pentylenetetrazol (PTZ) induced seizures in mice.
Objective: To assess organoleptic, physicochemical, phytochemical and pharmacological activity of selected Ghrita formulations used to treat Apasmara.
Materials and method: Six marketed Ghrita formulations used for Apasmara, such as Baidyanath Brahmi Ghrita (BBG), Patanjali Brahmi Ghrita, Kotakkal Brahmi Ghrita, Panchagavya Ghrita, Mahapanchagavya Ghrita and Nirgundyadi Ghrita were selected for the study. Selected Ghrita formulations were subjected to physicochemical analysis (following pharmacopeial procedures), phytochemical screening and pharmacological profile for quality and therapeutic efficacy. The screening parameters included pH, viscosity, specific gravity, loss on drying, acid value, saponification value, peroxide value, iodine value, refractive index and rancidity determination, and other phytochemical tests for secondary metabolites.
Results: BBG demonstrates superior protection against the onset and duration of convulsions compared to alternative Ghrita formulations. As evidenced by its efficacy in mitigating PTZ-induced convulsions, BBG stands out as the optimal choice for exerting potent anticonvulsant effects.
Conclusion: In-vivo screening suggests BBG as a potential Ghrita preparation for treatment of epilepsy.
{"title":"Organoleptic, physicochemical, phytochemical and pharmacological evaluation of six medicated ghee used for Ayurvedic management of Epilepsy.","authors":"Snehal Moon, Nishikant Raut, Harshal Moon, Anmol Dhawande, Shailendra Gurav","doi":"10.1016/j.jaim.2024.100995","DOIUrl":"10.1016/j.jaim.2024.100995","url":null,"abstract":"<p><strong>Background: </strong>Ayurvedic formulations need to be explored and tested with biomedical techniques. Polyherbal medicated ghee (Ghrita) are recommended for the management of epilepsy (Apasmara) and prepared using specialized process (Snehapaka), as per classical textbooks of Ayurveda. So, the present study deals with the systematic examination of the effect of different marketed formulations for treating Apasmara on convulsive impairment in Pentylenetetrazol (PTZ) induced seizures in mice.</p><p><strong>Objective: </strong>To assess organoleptic, physicochemical, phytochemical and pharmacological activity of selected Ghrita formulations used to treat Apasmara.</p><p><strong>Materials and method: </strong>Six marketed Ghrita formulations used for Apasmara, such as Baidyanath Brahmi Ghrita (BBG), Patanjali Brahmi Ghrita, Kotakkal Brahmi Ghrita, Panchagavya Ghrita, Mahapanchagavya Ghrita and Nirgundyadi Ghrita were selected for the study. Selected Ghrita formulations were subjected to physicochemical analysis (following pharmacopeial procedures), phytochemical screening and pharmacological profile for quality and therapeutic efficacy. The screening parameters included pH, viscosity, specific gravity, loss on drying, acid value, saponification value, peroxide value, iodine value, refractive index and rancidity determination, and other phytochemical tests for secondary metabolites.</p><p><strong>Results: </strong>BBG demonstrates superior protection against the onset and duration of convulsions compared to alternative Ghrita formulations. As evidenced by its efficacy in mitigating PTZ-induced convulsions, BBG stands out as the optimal choice for exerting potent anticonvulsant effects.</p><p><strong>Conclusion: </strong>In-vivo screening suggests BBG as a potential Ghrita preparation for treatment of epilepsy.</p>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"100995"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Medicinal plants are crucial for traditional healers in preparing remedies and also hold significant importance for the modern pharmaceutical industry, facilitating drug discovery processes. Accurate and effective identification and classification of Ethiopian indigenous medicinal plants are vital for their conservation and preservation. However, the existing identification and classification process is time-consuming, and tedious, and demands the expertise of specialists. Botanists traditionally rely on traditional and experience-based methods for identifying various medicinal plant species.
Objective
This research aims to develop an efficient deep learning model through transfer learning for the identification and classification of Ethiopian indigenous medicinal plant species.
Materials and methods
A custom dataset of 1853 leaf images from 35 species was prepared and labeled by botanist experts. Experiments have been done with the use of pretrained deep learning models, specifically VGG16, VGG19, Inception-V3, and Xception.
Results
The results demonstrate that fine-tuning the models significantly improves training and test accuracy, indicating the potential of deep learning in this domain. VGG19 outperforms other models with a test accuracy of 94%, followed by VGG16, Inception-V3, and Xception with test accuracies of 92%, 91%, and 87%, respectively. The study successfully addresses the challenges in the identification and classification of Ethiopian indigenous medicinal plant species.
Conclusion
With an inspiring accuracy performance of 95%, it can be concluded that fine-tuning emerged as a highly effective strategy for boosting the performance of deep learning models.
{"title":"Deep learning for Ethiopian indigenous medicinal plant species identification and classification","authors":"Mulugeta Adibaru Kiflie , Durga Prasad Sharma , Mesfin Abebe Haile","doi":"10.1016/j.jaim.2024.100987","DOIUrl":"10.1016/j.jaim.2024.100987","url":null,"abstract":"<div><h3>Background</h3><div>Medicinal plants are crucial for traditional healers in preparing remedies and also hold significant importance for the modern pharmaceutical industry, facilitating drug discovery processes. Accurate and effective identification and classification of Ethiopian indigenous medicinal plants are vital for their conservation and preservation. However, the existing identification and classification process is time-consuming, and tedious, and demands the expertise of specialists. Botanists traditionally rely on traditional and experience-based methods for identifying various medicinal plant species.</div></div><div><h3>Objective</h3><div>This research aims to develop an efficient deep learning model through transfer learning for the identification and classification of Ethiopian indigenous medicinal plant species.</div></div><div><h3>Materials and methods</h3><div>A custom dataset of 1853 leaf images from 35 species was prepared and labeled by botanist experts. Experiments have been done with the use of pretrained deep learning models, specifically VGG16, VGG19, Inception-V3, and Xception.</div></div><div><h3>Results</h3><div>The results demonstrate that fine-tuning the models significantly improves training and test accuracy, indicating the potential of deep learning in this domain. VGG19 outperforms other models with a test accuracy of 94%, followed by VGG16, Inception-V3, and Xception with test accuracies of 92%, 91%, and 87%, respectively. The study successfully addresses the challenges in the identification and classification of Ethiopian indigenous medicinal plant species.</div></div><div><h3>Conclusion</h3><div>With an inspiring accuracy performance of 95%, it can be concluded that fine-tuning emerged as a highly effective strategy for boosting the performance of deep learning models.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"Article 100987"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In an Indian female patient diagnosed as an aggressive refractory Natural Killer/T-cell Lymphoma treated with radiotherapy followed by chemotherapy, long term overall survival (OS) of 10 years was achieved. She refused Bone Marrow Transplant (BMT) after relapse and opted 2nd line chemotherapy. After completion of conventional treatment, she started Oral Ayurvedic Medicines (OAM) which possess immunomodulatory, anti-inflammatory, and to a certain extent anti-cancer activity.
This female patient was diagnosed with Stage IIE NK/T-cell Lymphoma and treated with radiotherapy from May to July 2011 followed by 6 cycles of R – CHOP Protocol from August to November 2011. Within 3 months after completion of conventional treatment, the patient presented with a recurrence of palatal ulcer and the appearance of tender subcutaneous nodules on both legs. She visited Cancer Hospital for a further line of treatment. Her histopathological report of soft palate ulcer showed suspicion of Non-Hodgkin's Lymphoma (NHL) and a subcutaneous nodule over her right leg revealed cutaneous involvement by NHL. Oncologist advised Bone Marrow Transplant (BMT) after taking into consideration an early relapse and aggressiveness of the disease. However, the patient refused BMT and opted 6 cycles of SMILE protocol chemotherapy taken from October 2012 to January 2013. The patient is under OAM of our centre consisting of a well-planned and personalized 6 sets of herbo-mineral metallic Ayurvedic medicines to minimize the side effects of chemotherapy as well as to boost immunity to prevent further recurrence of the disease. Her quality of life is improved significantly without any disease recurrence to date.
In this case of Refractory Natural Killer/T-cell Lymphoma having poor prognosis, 10 years OS after starting Ayurvedic treatment is reported. It has been achieved by personalized adjunct Ayurvedic treatment consisting combination of oral herbo-mineral metallic medicines.
{"title":"Improved quality of life of a patient with refractory aggressive Natural Killer/ T-cell lymphoma (NKTCL) on adjunct Ayurvedic treatment protocol: A case report of ten-years follow-up","authors":"Sadanand Sardeshmukh, Vineeta Deshmukh, Arvind Kulkarni, Vasanti Godse, Shrinivas Datar, Swapna Kulkarni, Sushama Bhuvad, Sandeep Chavan","doi":"10.1016/j.jaim.2024.100968","DOIUrl":"10.1016/j.jaim.2024.100968","url":null,"abstract":"<div><div>In an Indian female patient diagnosed as an aggressive refractory Natural Killer/T-cell Lymphoma treated with radiotherapy followed by chemotherapy, long term overall survival (OS) of 10 years was achieved. She refused Bone Marrow Transplant (BMT) after relapse and opted 2nd line chemotherapy. After completion of conventional treatment, she started Oral Ayurvedic Medicines (OAM) which possess immunomodulatory, anti-inflammatory, and to a certain extent anti-cancer activity.</div><div>This female patient was diagnosed with Stage IIE NK/T-cell Lymphoma and treated with radiotherapy from May to July 2011 followed by 6 cycles of R – CHOP Protocol from August to November 2011. Within 3 months after completion of conventional treatment, the patient presented with a recurrence of palatal ulcer and the appearance of tender subcutaneous nodules on both legs. She visited Cancer Hospital for a further line of treatment. Her histopathological report of soft palate ulcer showed suspicion of Non-Hodgkin's Lymphoma (NHL) and a subcutaneous nodule over her right leg revealed cutaneous involvement by NHL. Oncologist advised Bone Marrow Transplant (BMT) after taking into consideration an early relapse and aggressiveness of the disease. However, the patient refused BMT and opted 6 cycles of SMILE protocol chemotherapy taken from October 2012 to January 2013. The patient is under OAM of our centre consisting of a well-planned and personalized 6 sets of herbo-mineral metallic Ayurvedic medicines to minimize the side effects of chemotherapy as well as to boost immunity to prevent further recurrence of the disease. Her quality of life is improved significantly without any disease recurrence to date.</div><div>In this case of Refractory Natural Killer/T-cell Lymphoma having poor prognosis, 10 years OS after starting Ayurvedic treatment is reported. It has been achieved by personalized adjunct Ayurvedic treatment consisting combination of oral herbo-mineral metallic medicines.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"Article 100968"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The rising prevalence of colorectal cancer (CRC) may be attributed to various nutritional and behavioural factors, making both factors as important topics for discussion to the layman and the oncology community.
Objective
To explore additional dietary risk factors, other than those already known, according to the Ayurvedic perspective in CRC patients.
Methods
Detail dietary data was collected from 420 patients of CRC and 116 healthy volunteers registered at our institute with the help of a food frequency questionnaire. Descriptive analysis was done by plotting radar charts, whereas the logistic regression models were used to calculate the adjusted Odd Ratios (ORs) associated with consumption of green chilli, red chilli powder and curd, individually and in combinations.
Results
The controls in the present study were younger, had more males, the majority of them belonged to middle- and lower-income groups and had a family history of cancer as compared with cohort of case studies. Green chilli consumption was found to be the maximum within the lower-income group (n = 18, 66.67%), while that of red chilli (n = 150, 48.23%), and curd (n = 107, 34.04%) within the middle class. Maximum consumption of green chillies (Males n = 48, 29.27%; Females n = 36, 21.95%), red chillies (Males n = 40, 29.85%; Females n = 16, 24.61%) and curd (Males n = 31, 28.97%) was observed in the age group 46 to 60 irrespective of sex. Tobacco was found to be the most common addiction in all groups. The maximum number of patients frequently consuming these three dietary items presented majorly with rectal cancer, and liver metastasis and were in advanced grade and stage of cancer. Curd and curd with red chilli powder had a significant association with the development of CRC with an OR of 2.7280 (95% CI 1.6346 to 4.5531) and 5.0806 (95% CI 2.4015 to 10.7485), respectively, which was highly significant (p < 0.0001). Green chilli was notably an associated risk with an OR of 2.0095 (95% CI 1.3258 to 3.0458), which was also statistically significant (p = 0.001). Red chilli powder and green chilli with curd had ORs as 1.6917 (95% CI 1.1105 to 2.5771) and 2.1778 (95% CI 1.1591 to 4.0918) with p = 0.0144 and 0.0156, respectively.
Conclusion
In the present study, green chilli, red chilli, and curd are identified as additional dietary risk factors for colorectal cancers, owing to their ability to produce chronic inflammation leading to various inflammatory conditions including cancer.
{"title":"Ayurvedic perspective of dietary risk factors of colorectal cancers - A hospital-based case control study","authors":"Sadanand Sardeshmukh, Vineeta Deshmukh, Vasanti Godse, Shweta Gujar, Sneha Dalvi, Swapna Kulkarni, Sushama Bhuvad, Nilambari Sardeshmukh, Bhagyashree Sardeshmukh, Dhananjay Deshpande, Vinita Awalkanthe, Amruta Salunkhe, Anita Redekar, Suchita Vaidya, Sandeep Chavan","doi":"10.1016/j.jaim.2024.100969","DOIUrl":"10.1016/j.jaim.2024.100969","url":null,"abstract":"<div><h3>Background</h3><div>The rising prevalence of colorectal cancer (CRC) may be attributed to various nutritional and behavioural factors, making both factors as important topics for discussion to the layman and the oncology community.</div></div><div><h3>Objective</h3><div>To explore additional dietary risk factors, other than those already known, according to the Ayurvedic perspective in CRC patients.</div></div><div><h3>Methods</h3><div>Detail dietary data was collected from 420 patients of CRC and 116 healthy volunteers registered at our institute with the help of a food frequency questionnaire. Descriptive analysis was done by plotting radar charts, whereas the logistic regression models were used to calculate the adjusted Odd Ratios (ORs) associated with consumption of green chilli, red chilli powder and curd, individually and in combinations.</div></div><div><h3>Results</h3><div>The controls in the present study were younger, had more males, the majority of them belonged to middle- and lower-income groups and had a family history of cancer as compared with cohort of case studies. Green chilli consumption was found to be the maximum within the lower-income group (n = 18, 66.67%), while that of red chilli (n = 150, 48.23%), and curd (n = 107, 34.04%) within the middle class. Maximum consumption of green chillies (Males n = 48, 29.27%; Females n = 36, 21.95%), red chillies (Males n = 40, 29.85%; Females n = 16, 24.61%) and curd (Males n = 31, 28.97%) was observed in the age group 46 to 60 irrespective of sex. Tobacco was found to be the most common addiction in all groups. The maximum number of patients frequently consuming these three dietary items presented majorly with rectal cancer, and liver metastasis and were in advanced grade and stage of cancer. Curd and curd with red chilli powder had a significant association with the development of CRC with an OR of 2.7280 (95% CI 1.6346 to 4.5531) and 5.0806 (95% CI 2.4015 to 10.7485), respectively, which was highly significant (p < 0.0001). Green chilli was notably an associated risk with an OR of 2.0095 (95% CI 1.3258 to 3.0458), which was also statistically significant (p = 0.001). Red chilli powder and green chilli with curd had ORs as 1.6917 (95% CI 1.1105 to 2.5771) and 2.1778 (95% CI 1.1591 to 4.0918) with p = 0.0144 and 0.0156, respectively.</div></div><div><h3>Conclusion</h3><div>In the present study<strong>,</strong> green chilli, red chilli, and curd are identified as additional dietary risk factors for colorectal cancers, owing to their ability to produce chronic inflammation leading to various inflammatory conditions including cancer.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"Article 100969"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-12-02DOI: 10.1016/j.jaim.2024.101048
Graeme Stringer
A narrative review of chronic periodontitis, a dysfunctional inflammatory disease of the gums finds it is linked to over 60 systemic diseases and has been shown to reduce lifespan. Termed dantamoolaroga in Ayurvedic medicine, the causative vitiated doshas for the 17 types of dantamoolaroga have been described and give leads as to systemic imbalances behind the diseases. By improving periodontal (gum) health, improvements in type 2 diabetes, cardiovascular and other chronic inflammatory markers have been shown. Systemic chronic inflammation is the underlying cause of non-communicable diseases, including periodontitis, cardiovascular diseases, respiratory, diabetes and metabolic diseases, cancer and others, now contributing over 70% of worldwide deaths. It is found that oral health reflects systemic health and provides a window into general health. As personalised medicine is being developed to assess the multiple pathophysiological factors underlying systemic chronic inflammation, it is noted that Ayurveda has a comprehensive approach to diagnosis with the 10 fold assessment (Dashavidha Praiksha) and eight fold examinations (Astasthana Pariksha) being considered the original personalised medicine. There are Ayurvedic clinical correlates and causes of systemic chronic inflammation assisting clinical evaluation and treatment planning. Ayurvedic diagnostic measures for general health and periodontal health need validation in today's terms to strengthen the scientific credentials and enable better clinical use of both systems in an integrative manner. Inclusion of clinical assessment of periodontal health status at consultation, particularly for any chronic disease, is strongly recommended to gain insight into a widespread systemic chronic inflammation marker. The multiple Ayurvedic clinical measures for chronic inflammation provides potential for lines of research that complement the current molecular based approaches.
{"title":"Chronic periodontitis, dantamoolaroga, indicates chronic systemic inflammation and reduces longevity.","authors":"Graeme Stringer","doi":"10.1016/j.jaim.2024.101048","DOIUrl":"10.1016/j.jaim.2024.101048","url":null,"abstract":"<p><p>A narrative review of chronic periodontitis, a dysfunctional inflammatory disease of the gums finds it is linked to over 60 systemic diseases and has been shown to reduce lifespan. Termed dantamoolaroga in Ayurvedic medicine, the causative vitiated doshas for the 17 types of dantamoolaroga have been described and give leads as to systemic imbalances behind the diseases. By improving periodontal (gum) health, improvements in type 2 diabetes, cardiovascular and other chronic inflammatory markers have been shown. Systemic chronic inflammation is the underlying cause of non-communicable diseases, including periodontitis, cardiovascular diseases, respiratory, diabetes and metabolic diseases, cancer and others, now contributing over 70% of worldwide deaths. It is found that oral health reflects systemic health and provides a window into general health. As personalised medicine is being developed to assess the multiple pathophysiological factors underlying systemic chronic inflammation, it is noted that Ayurveda has a comprehensive approach to diagnosis with the 10 fold assessment (Dashavidha Praiksha) and eight fold examinations (Astasthana Pariksha) being considered the original personalised medicine. There are Ayurvedic clinical correlates and causes of systemic chronic inflammation assisting clinical evaluation and treatment planning. Ayurvedic diagnostic measures for general health and periodontal health need validation in today's terms to strengthen the scientific credentials and enable better clinical use of both systems in an integrative manner. Inclusion of clinical assessment of periodontal health status at consultation, particularly for any chronic disease, is strongly recommended to gain insight into a widespread systemic chronic inflammation marker. The multiple Ayurvedic clinical measures for chronic inflammation provides potential for lines of research that complement the current molecular based approaches.</p>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"101048"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-12-03DOI: 10.1016/j.jaim.2024.101022
Amit Sarhyal, Sameeran Chate, Basavaraj R Tubaki, Rajat Thakur
Background: Role of Ayurveda medications in the management of Major depressive disorder (MDD) is explored.
Objective: To evaluate the effect of Brahmi vati and Aswagandarista in the management of MDD.
Methods: Study was a Randomized, Controlled, parallel group comparative clinical trial. Fifty patients meeting the MDD (DSM V) diagnostic criteria from teaching hospital were recruited in the study. They were divided in two 2 groups. Control group were administered with Escitalopram 10 mg twice a day. Ayurveda group were intervened with tablet Brahmi vati 500 mg thrice a day and Liquid Aswagandarista 10 ml thrice a day. Interventions were for 60 days. Assessments were done on every 15th day. Assessments criteria included Hamilton Depression Rating scale (HDRS), Hamilton Anxiety Rating scale (HARS), UKU Side effect scale (UKU), Brief Psychotic Rating Scale (BPRS), WHO quality of life -BREF (WHOQOL-BREF), Pittsburgh Sleep Quality Index (PSQI) and Clinical Global Impression scales (CGI) were assessed at all the time points. Blood parameters like Haemoglobin, Serum creatinine and Liver function tests were evaluated at pre and post study.
Results: Between group comparison showed significant improvements in WHOQOL-Bref (p < 0.001), UKU (p = 0.04) favouring Ayurveda group and PSQI (p = 0.02) improvements in control group. Improvements in other parameters were comparable. Within group assessment showed significant (p < 0.001) improvement in HDRS, HARS, BPRS, CGI-S, CGI-GI in both the groups. Liver function tests and serum creatines were within normative limits.
Conclusion: Ayurveda medications produced significant improvements comparable to escitalopram with additional advantages in quality of life and side effects profile.
背景：探讨阿育吠陀药物在重度抑郁症（MDD）治疗中的作用。目的：评价婆罗米泻和芦花泻治疗重度抑郁症的疗效。方法：采用随机、对照、平行组对照临床试验。本研究从教学医院招募50例符合重度抑郁症（DSM V）诊断标准的患者。他们被分成两组。对照组患者给予艾司西酞普兰10 mg，每日2次。阿育吠陀组给予婆罗梵片500 mg / d，阿楝液10 ml / d。干预期为60天。每隔15天进行一次评估。评估标准包括汉密尔顿抑郁评定量表（HDRS）、汉密尔顿焦虑评定量表（HARS）、UKU副作用评定量表（UKU）、简短精神病评定量表（BPRS）、WHO生活质量-BREF （WHOQOL-BREF）、匹兹堡睡眠质量指数（PSQI）和临床总体印象量表（CGI）。在研究前后评估血红蛋白、血清肌酐和肝功能等血液参数。结果：组间比较显示WHOQOL-Bref有显著改善(p)。结论：阿育吠陀药物与艾司西酞普兰相比有显著改善，在生活质量和副作用方面有额外的优势。
{"title":"Efficacy of Brahmi vati and Aswagandharista in major depressive disorder: A randomized controlled trial.","authors":"Amit Sarhyal, Sameeran Chate, Basavaraj R Tubaki, Rajat Thakur","doi":"10.1016/j.jaim.2024.101022","DOIUrl":"10.1016/j.jaim.2024.101022","url":null,"abstract":"<p><strong>Background: </strong>Role of Ayurveda medications in the management of Major depressive disorder (MDD) is explored.</p><p><strong>Objective: </strong>To evaluate the effect of Brahmi vati and Aswagandarista in the management of MDD.</p><p><strong>Methods: </strong>Study was a Randomized, Controlled, parallel group comparative clinical trial. Fifty patients meeting the MDD (DSM V) diagnostic criteria from teaching hospital were recruited in the study. They were divided in two 2 groups. Control group were administered with Escitalopram 10 mg twice a day. Ayurveda group were intervened with tablet Brahmi vati 500 mg thrice a day and Liquid Aswagandarista 10 ml thrice a day. Interventions were for 60 days. Assessments were done on every 15th day. Assessments criteria included Hamilton Depression Rating scale (HDRS), Hamilton Anxiety Rating scale (HARS), UKU Side effect scale (UKU), Brief Psychotic Rating Scale (BPRS), WHO quality of life -BREF (WHOQOL-BREF), Pittsburgh Sleep Quality Index (PSQI) and Clinical Global Impression scales (CGI) were assessed at all the time points. Blood parameters like Haemoglobin, Serum creatinine and Liver function tests were evaluated at pre and post study.</p><p><strong>Results: </strong>Between group comparison showed significant improvements in WHOQOL-Bref (p < 0.001), UKU (p = 0.04) favouring Ayurveda group and PSQI (p = 0.02) improvements in control group. Improvements in other parameters were comparable. Within group assessment showed significant (p < 0.001) improvement in HDRS, HARS, BPRS, CGI-S, CGI-GI in both the groups. Liver function tests and serum creatines were within normative limits.</p><p><strong>Conclusion: </strong>Ayurveda medications produced significant improvements comparable to escitalopram with additional advantages in quality of life and side effects profile.</p>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"101022"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11663963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01Epub Date: 2024-12-02DOI: 10.1016/j.jaim.2024.101033
Varsha B Gonugade, Sameeran S Chate, Basavaraj R Tubaki, Rajat Thakur
Background: Ayurvedic intervention (Brahmi Vati with Saraswatarista) is explored for their possible role in management of Generalized Anxiety Disorder (GAD), a common psychiatric disorder.
Objective: The objective of the study was to evaluate the efficacy of Brahmi Vati and Saraswatarista in GAD.
Methods: Study is a randomized controlled clinical trial. Patients (n = 50) of GAD (Diagnostic and Statistical Manual of Mental Disorders (DSM-5 criteria), 18-60 years of age, either sex participated in the study. Participants were randomly divided into two groups. Group A, received escitalopram 10 mg/day for first 10 days followed by 20 mg/day for next 50 days. Group B, received Ayurvedic intervention (Brahmi Vati 500 mg thrice a day (TID) and Saraswatarista 10 ml TID) for 60 days. Assessments were with clinical parameters like Hamilton Anxiety Rating Scale (HARS), GAD 7 scale (GAD 7), Beck Depression Inventory scale (BDI), Epworth sleepiness scale (ESS), Pittsburgh Sleep Quality Index (PSQI), WHO Quality of Life- BREF (WHOQOL-BREF), Clinical Global Improvement scale (CGI) and UKU-Side effect scale (UKU). These clinical assessments were measured on every 15th day during the intervention. Haemoglobin, liver function test (LFT), serum creatinine, serum urea were assessed before and after the study.
Results: Study results indicate that both the groups were comparable in HARS, GAD7, BDI, WHOQOL-Bref and CGI-Severity. Group B was better in PSQI (standard mean difference = 0.87, 95% CI: 0.28, 1.43), ESS (standard mean difference = 1.42, 95% CI: 0.78, 2.02), CGI [global improvement (standard mean difference = 0.82, 95% CI: 0.23,1.28) and efficacy index (standard mean difference = 0.97, 95% CI: 0.37,1.54)] and had better adverse events profile (standard mean difference = 0.79, 95% CI: 0.21, 1.36). Both the groups had a good safety profile assessed through liver and renal profiles.
Conclusion: Ayurveda interventions has additional advantages likes improvements in sleep profile, lesser adverse events and better global improvement in management of GAD. CTRI Registration Number is CTRI/2020/09/027750.
{"title":"Efficacy of ayurveda medications, Brahmi vati and Saraswatarista, in generalized anxiety disorder- a randomized controlled trial.","authors":"Varsha B Gonugade, Sameeran S Chate, Basavaraj R Tubaki, Rajat Thakur","doi":"10.1016/j.jaim.2024.101033","DOIUrl":"10.1016/j.jaim.2024.101033","url":null,"abstract":"<p><strong>Background: </strong>Ayurvedic intervention (Brahmi Vati with Saraswatarista) is explored for their possible role in management of Generalized Anxiety Disorder (GAD), a common psychiatric disorder.</p><p><strong>Objective: </strong>The objective of the study was to evaluate the efficacy of Brahmi Vati and Saraswatarista in GAD.</p><p><strong>Methods: </strong>Study is a randomized controlled clinical trial. Patients (n = 50) of GAD (Diagnostic and Statistical Manual of Mental Disorders (DSM-5 criteria), 18-60 years of age, either sex participated in the study. Participants were randomly divided into two groups. Group A, received escitalopram 10 mg/day for first 10 days followed by 20 mg/day for next 50 days. Group B, received Ayurvedic intervention (Brahmi Vati 500 mg thrice a day (TID) and Saraswatarista 10 ml TID) for 60 days. Assessments were with clinical parameters like Hamilton Anxiety Rating Scale (HARS), GAD 7 scale (GAD 7), Beck Depression Inventory scale (BDI), Epworth sleepiness scale (ESS), Pittsburgh Sleep Quality Index (PSQI), WHO Quality of Life- BREF (WHOQOL-BREF), Clinical Global Improvement scale (CGI) and UKU-Side effect scale (UKU). These clinical assessments were measured on every 15th day during the intervention. Haemoglobin, liver function test (LFT), serum creatinine, serum urea were assessed before and after the study.</p><p><strong>Results: </strong>Study results indicate that both the groups were comparable in HARS, GAD7, BDI, WHOQOL-Bref and CGI-Severity. Group B was better in PSQI (standard mean difference = 0.87, 95% CI: 0.28, 1.43), ESS (standard mean difference = 1.42, 95% CI: 0.78, 2.02), CGI [global improvement (standard mean difference = 0.82, 95% CI: 0.23,1.28) and efficacy index (standard mean difference = 0.97, 95% CI: 0.37,1.54)] and had better adverse events profile (standard mean difference = 0.79, 95% CI: 0.21, 1.36). Both the groups had a good safety profile assessed through liver and renal profiles.</p><p><strong>Conclusion: </strong>Ayurveda interventions has additional advantages likes improvements in sleep profile, lesser adverse events and better global improvement in management of GAD. CTRI Registration Number is CTRI/2020/09/027750.</p>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"101033"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Although empirical data on the influence of Ayurveda on Chemo/Radiotherapy-induced side effects are limited, its methodological framework, grounded in a 'systems thinking' perspective, enables the precise delineation of the pathogenic stage of these side effects. This, in turn, facilitates the development of a strategy to address the decline in the quality of life parameters commonly associated with cancer treatment. Ayurveda personalized approach to disease management typically involves providing customized diets, lifestyle adjustments, medications, and detoxification therapies that target the entire body.
We present a case involving a patient with numbness and pain in the right hand after undergoing chemotherapy who was referred to us by an oncologist for symptom management. This case report demonstrates the Ayurveda approach for establishing the etiology, pathogenesis, pathophysiology, and treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN) resulting from taxane-based chemotherapy. Following Ayurveda intervention, the patient exhibited significant improvements in symptoms and quality of life parameters.
This case report systematically illustrates the application of Ayurveda approach in CIPN management.
{"title":"Classical ayurveda management of TCH (taxane, carboplatin, and herceptin) based chemotherapy induced peripheral neuropathy- A case report","authors":"Zankhana Buch , Suprabha Hegde , Aishwarya Lakshmi , Swathi Bhat","doi":"10.1016/j.jaim.2024.101044","DOIUrl":"10.1016/j.jaim.2024.101044","url":null,"abstract":"<div><p>Although empirical data on the influence of Ayurveda on Chemo/Radiotherapy-induced side effects are limited, its methodological framework, grounded in a 'systems thinking' perspective, enables the precise delineation of the pathogenic stage of these side effects. This, in turn, facilitates the development of a strategy to address the decline in the quality of life parameters commonly associated with cancer treatment. Ayurveda personalized approach to disease management typically involves providing customized diets, lifestyle adjustments, medications, and detoxification therapies that target the entire body.</p><p>We present a case involving a patient with numbness and pain in the right hand after undergoing chemotherapy who was referred to us by an oncologist for symptom management. This case report demonstrates the Ayurveda approach for establishing the etiology, pathogenesis, pathophysiology, and treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN) resulting from taxane-based chemotherapy. Following Ayurveda intervention, the patient exhibited significant improvements in symptoms and quality of life parameters.</p><p>This case report systematically illustrates the application of Ayurveda approach in CIPN management.</p></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 5","pages":"Article 101044"},"PeriodicalIF":1.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947624001591/pdfft?md5=54366e63e4f13d6b195d6ea5fecbf6b7&pid=1-s2.0-S0975947624001591-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号